$879 Million is the total value of Column Group LLC's 7 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 80.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
NGM | NGM Biopharmaceuticals Inc | $323,626,000 | +6.6% | 15,396,116 | 0.0% | 36.81% | -14.3% | |
New | Tenaya Therapeutics, Inc. | $194,116,000 | – | 9,400,290 | +100.0% | 22.08% | – | |
ORIC | ORIC Pharmaceuticals Inc. | $99,703,000 | +18.2% | 4,768,181 | 0.0% | 11.34% | -5.0% | |
RVMD | Revolution Medicines Inc | $92,083,000 | -13.3% | 3,347,245 | 0.0% | 10.48% | -30.3% | |
New | Surrozen, Inc. | $65,477,000 | – | 9,248,129 | +100.0% | 7.45% | – | |
New | eFFECTOR Therapeutics Inc | $60,546,000 | – | 4,309,329 | +100.0% | 6.89% | – | |
RAPT | Sell | RAPT Therapeutics Inc | $43,532,000 | -64.8% | 1,402,008 | -63.9% | 4.95% | -71.7% |
CNST | Exit | Constellation Pharmaceuticals Inc. | $0 | – | -2,626,631 | -100.0% | -12.57% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-12
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
NGM Biopharmaceuticals Inc | 12 | Q3 2023 | 52.5% |
Revolution Medicines Inc | 12 | Q3 2023 | 36.3% |
RAPT Therapeutics Inc | 12 | Q3 2023 | 29.6% |
ORIC Pharmaceuticals Inc. | 12 | Q3 2023 | 14.6% |
Tenaya Therapeutics, Inc. | 9 | Q3 2023 | 24.2% |
Surrozen, Inc. | 9 | Q3 2023 | 8.2% |
eFFECTOR Therapeutics Inc | 9 | Q3 2023 | 6.9% |
Constellation Pharmaceuticals Inc. | 3 | Q2 2021 | 12.6% |
Nurix Therapeutics Inc | 2 | Q1 2021 | 16.1% |
Gritstone Oncology Inc | 1 | Q4 2020 | 0.3% |
View Column Group LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-09 |
13F-HR | 2023-11-13 |
13F-HR | 2023-07-24 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-12 |
4 | 2022-05-27 |
4 | 2022-05-25 |
13F-HR | 2022-05-16 |
View Column Group LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.